Literature DB >> 17117309

Left ventricular remodeling after myocardial infarction: past, present, and future.

Satish R Tiyyagura1, Sean P Pinney.   

Abstract

Medical advances in the care of cardiac patients have resulted in more patients surviving an acute myocardial infarction (MI) than ever before. Each year hundreds of thousands of these survivors undergo remodeling of their left ventricle and often progress to clinical congestive heart failure. The extent of remodeling has been linked to the size of the infarct, whether or not the myocardium has been revascularized, and the control of loading conditions. The extent of infarction can be measured several ways, including the amount of enzyme released as well as infarct imaging with nuclear perfusion or magnetic resonance imaging. Methods to prevent adverse remodeling of the ventricle have included pharmacotherapy with beta-blockers, nitrates, and modulators of the renin-angiotensin-aldosterone system. Surgical intervention has proven useful for select patients with aneurysmal areas of remodeling. Researchers are now investigating several approaches to preventing and reversing cardiac remodeling. These include the use of stem cells to regenerate myocardium and post-infarct pacing to prevent remodeling. Improved therapies are needed to help reduce the number of patients progressing from myocardial infarction to end-stage heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17117309

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  23 in total

1.  Non-invasive Monitoring of Angiogenesis in Cardiology.

Authors:  Martin Rodriguez-Porcel
Journal:  Curr Cardiovasc Imaging Rep       Date:  2009-02

Review 2.  Mesenchymal stem cells for the treatment of heart failure.

Authors:  Shunsuke Ohnishi; Hajime Ohgushi; Soichiro Kitamura; Noritoshi Nagaya
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Early NADPH oxidase-2 activation is crucial in phenylephrine-induced hypertrophy of H9c2 cells.

Authors:  Nynke E Hahn; René J P Musters; Jan M Fritz; Patrick J Pagano; Alexander B A Vonk; Walter J Paulus; Albert C van Rossum; Christof Meischl; Hans W M Niessen; Paul A J Krijnen
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

4.  Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction.

Authors:  P Locatelli; F D Olea; A Hnatiuk; A De Lorenzi; M Cerdá; C S Giménez; D Sepúlveda; R Laguens; A Crottogini
Journal:  Gene Ther       Date:  2015-03-19       Impact factor: 5.250

5.  High-dose intramyocardial HMGB1 induces long-term cardioprotection in sheep with myocardial infarction.

Authors:  María Del Rosario Bauzá; Carlos Sebastián Giménez; Paola Locatelli; Andrea De Lorenzi; Anna Hnatiuk; Maurizio C Capogrossi; Alberto Crottogini; Luis Cuniberti; Fernanda Daniela Olea
Journal:  Drug Deliv Transl Res       Date:  2019-10       Impact factor: 4.617

Review 6.  Post-infarct biomaterials, left ventricular remodeling, and heart failure: is good good enough?

Authors:  Fouad A Zouein; Carlos Zgheib; Kenneth W Liechty; George W Booz
Journal:  Congest Heart Fail       Date:  2012-05-22

Review 7.  Prevention of late postmyocardial infarction left ventricular remodeling: an update.

Authors:  Farouk Mookadam; Sherif E Moustafa
Journal:  Curr Heart Fail Rep       Date:  2009-12

8.  Mechanisms of Post-Infarct Left Ventricular Remodeling.

Authors:  Brent A French; Christopher M Kramer
Journal:  Drug Discov Today Dis Mech       Date:  2007

9.  Unexpected anti-hypertrophic responses to low-level stimulation of protease-activated receptors in adult rat cardiomyocytes.

Authors:  Anke C Fender; Goran Pavic; Grant R Drummond; Gregory J Dusting; Rebecca H Ritchie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-01       Impact factor: 3.000

10.  The Effects of Fasudil at Different Doses on Acute Myocardial Infarction in Rats.

Authors:  Lijuan Tan; Nana Pan; Lingfan Yu; Renchao Yu; Bin Yang
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.